Trends in the development of human stem cell-based non-animal drug testing models.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Organoid models: Regulations and prospects for the development of investigational new drugs.Chinese medical journal · 2026
   Review
2. Exploring UVA1-Induced Metabolic Effects in Different In Vitro, Ex Vivo, and In Vivo Systems.Metabolites · 2026
   Article
3. Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening.Biomolecules · 2024
   Review
4. In vitro modelling of bacterial pneumonia: a comparative analysis of widely applied complex cell culture models.FEMS microbiology reviews · 2024
   Review
5. Replacement of animal testing by integrated approaches to testing and assessment (IATA): a call for in vivitrosi.Archives of toxicology · 2022
   Review
6. Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology.Micromachines · 2021
   Review
7. Human Embryo Models and Drug Discovery.International journal of molecular sciences · 2021
   Review
8. Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.Cancers · 2020
   Review
9. Progress of Induced Pluripotent Stem Cell-Derived Renal Organoids in Clinical Application.Kidney diseases (Basel, Switzerland)
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as